Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project.
Stefano PorruMaria Grazia Lourdes MonacoGianluca SpiteriAngela CartaGulser CaliskanConcepción ViolánPere Torán-MonserratLuigi VimercatiSilvio TafuriPaolo BoffettaFrancesco Saverio ViolanteEmma SalaEmanuele SansoneFabriziomaria GobbaLoretta CasolariAndreas WieserChristian JankeAdonina TardonMarta Maria Rodriguez-SuarezFilippo LivieroMaria Luisa ScapellatoMarco dell'OmoNicola MurgiaDana MatesVioleta Claudia CalotaJozef StrhárskyMariana MrázováEnrico PiraAlessandro GodonoGreta Camilla MagnanoCorrado NegroGiuseppe Verlatonull nullPublished in: Journal of epidemiology and global health (2023)
The risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics.